Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA)

Military Medicine

Volumn 177, Issue 12, 2012, Pages 1455-1459

  Eliason, Michael J ^a   Eichner, Amy ^b   Cancio, Anthony ^a   Bestervelt, Lori ^c   Adams, Bruce D ^d   Deuster, Patricia A ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b US Anti Doping Agency   (United States)

^c NSF INTERNATIONAL   (United States)

^d WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3-DIMETHYLAMYLAMINE; 4 METHYL 2 HEXYLAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; FATALITY; FEMALE; HEART ARREST; HUMAN; MALE; MULTIPLE ORGAN FAILURE; RUNNING; SEPSIS; SOLDIER; SUDDEN DEATH;

ADULT; AMINES; DEATH, SUDDEN; DIETARY SUPPLEMENTS; DISSEMINATED INTRAVASCULAR COAGULATION; FATAL OUTCOME; FEMALE; HEART ARREST; HUMANS; MALE; MILITARY PERSONNEL; MULTIPLE ORGAN FAILURE; RUNNING; SEPSIS; SYMPATHOMIMETICS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84871445773     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.7205/MILMED-D-12-00265     Document Type: Article

References (62)

1. Scoville SL, Gardner JW, Magill AJ, Potter RN, Kark JA: Nontraumatic deaths during U.S. Armed Forces basic training, 1977-2001. Am J Prev Med 2004; 26(3): 205-12.
2. Carter R 3rd, Cheuvront SN, Williams JO, et al: Epidemiology of hospitalizations and deaths from heat illness in soldiers. Med Sci Sports Exerc 2005; 37(8): 1338-44.
3. Eckart RE, Gentlesk PJ, Shry EA: Differential manifestation of cardiovascular complaints as a function of utilization of ergogenic supplements. Pacing Clin Electrophysiol 2010; 33(3): 286-9.
4. Dehoney S, Wellein M: Rhabdomyolysis associated with the nutritional supplement Hydroxycut. Am J Health Syst Pharm 2009; 66(2): 142-8.
5. Burke J, Seda G, Allen D, Knee TS: A case of severe exercise-induced rhabdomyolysis associated with a weight-loss dietary supplement. Mil Med 2007; 172(6): 656-8.
6. Oh RC, Henning JS: Exertional heatstroke in an infantry soldier taking ephedra-containing dietary supplements. Mil Med 2003; 168(6): 429-30.
7. Hughes J, Shelton B, Hughes T: Suspected dietary supplement injuries in special operations soldiers. J Spec Oper Med 2010; 10(3): 14-24.
8. Fong TL, Klontz KC, Canas-Coto A, et al: Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010; 105(7): 1561-6.
9. Lobb A: Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol 2009; 15(14): 1786-7.
10. Palamar J: How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy 2011; 99(1): 1-9.
11. Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services: Dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; final rule. J Pain Palliat Care Pharmacother 2004; 18(3): 95-107.
12. Bloomer RJ, Fisher-Wellman KH, Hammond KG, et al: Dietary supplement increases plasma norepinephrine, lipolysis, and metabolic rate in resistance trained men. J Int Soc Sports Nutr 2009; 6: 4.
13. Bloomer RJ, Canale RE, Blankenship MM, et al: Effect of the dietary supplement Meltdown on catecholamine secretion, markers of lipolysis, and metabolic rate in men and women: a randomized, placebo controlled, cross-over study. Lipids Health Dis 2009; 8: 32.
14. Acheson KJ, Gremaud G, Meirim I, et al: Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr 2004; 79(1): 40-6.
15. Greenway FL, De Jonge L, Blanchard D, Frisard M, Smith SR: Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004; 12(7): 1152-7.
16. Vukovich MD, Schoorman R, Heilman C, Jacob P 3rd, Benowitz NL: Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure. Clinical Exp Pharmacol Physiol 2005; 32(1-2): 47-53.
17. Stahl CE, Borlongan CV, Szerlip M, Szerlip H: No pain, no gain-exercise-induced rhabdomyolysis associated with the performance enhancer herbal supplement ephedra. Med Sci Monit 2006; 12(9): CS81-4.
18. Gee P, Jackson S, Easton J: Another bitter pill: a case of toxicity from DMAA party pills. N Z Med J 2010; 123(1327): 124-7.
19. Vorce SP, Holler JM, Cawrse BM, Magluilo J Jr.: Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. J Anal Toxicol 2011; 35(3): 183-7.
20. Chen KK: Aliphatic versus aromatic amines as vasoconstrictors. Ann Otol Rhinol Laryngol 1948; 57(2): 287-97.
21. E. R. Squibb & Sons, Inc., et al: Notices: Withdrawal of Approval of New Drug Applications. Federal Register 48: 51425-604, Food and Drug Administration, November 9, 1983.
22. New and nonofficial remedies: methylhexamine; forthane. J Am Med Assoc 1950; 143(13): 1156.
23. Swanson EE, Chen KK: Comparison of pressor action of aliphatic amines. J Pharmacol Exp Ther 1946; 88(1): 10-3.
24. Rohrmann E, Shonle HA: Aminoalkanes as pressor substances. J Am Chem Soc 1944; 66(9): 1516-20.
25. Young R, Gabryszuk M, Glennon RA: (-)Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects. Pharmacol Biochem Behav 1998; 61(2): 169-73.
26. Sittig M: Pharmaceutical Manufacturing Encyclopedia. Vol 2, L-Z, Ed 2. Norwich, William Andrew Publishing, 1988.
27. Marsh DF: The comparative pharmacology of the isomeric hyptylamines. J Pharmacol Exp Ther 1948; 94(3): 225-31.
28. Swanson EE, Chen KK: Comparison of pressor action of alicyclic derivatives of aliphatic amines. J Pharmacol Exp Ther 1948; 93(4): 423-9.
29. Proviant Technologies: Geranamine. US patent 3,096,824. January 5, 2005. Available at http://geranamine.org/; accessed April 20, 2012.
30. Ping Z, Jun Q, Qing L: A study on the chemical constituents of geranium oil. J Guizhou Inst Technol 1996; 25.
31. Lisi A, Hasick N, Kazlauskas R, Goebel C: Studies of methylhexaneamine in supplements and geranium oil. Drug Test Anal 2011; 3(11-12): 873-6.
32. ElSohly MA, Gul W, ElSohly KM, et al: Methylhexanamine is not detectable in the essential oil of Pelargonium graveolens (geranium oil) GC/MS and LC/MS/MS investigation. J Anal Toxicol 2011. (in press).
33. Jones G: Caffeine and other sympathomimetic stimulants: modes of action and effects on sports performance. Essays Biochem 2008; 44: 109-23.
34. Shekelle PG, Hardy ML, Morton SC, et al: Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289(12): 1537-45.
35. Francaux M, Poortmans JR: Side effects of creatine supplementation in athletes. Int J Sports Physiol Perform 2006; 1(4): 311-23.
36. Kim HJ, Kim CK, Carpentier A, Poortmans JR: Studies on the safety of creatine supplementation. Amino Acids 2011; 40(5): 1409-18.
37. Crim MC, Calloway DH, Margen S: Creatine metabolism in men: urinary creatine and creatinine excretions with creatine feeding. J Nutr 1975; 105(4): 428-38.
38. Bailes JE, Cantu RC, Day AL: The neurosurgeon in sport: awareness of the risks of heatstroke and dietary supplements. Neurosurgery 2002; 51(2): 283-6; discussion 286-8.
39. Moffatt AC, Osselton MD, Widdop B, Galichet LY: Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material, Ed 3. London, Pharmaceutical Press, 2004.
40. Gee P, Tallon C, Long N, et al: Use of recreational drug 1,3-dimethylethylamine (DMAA) associated with cerebral hemorrhage. Ann Emerg Med 2012. (in press).
41. Anzalone ML, Green VS, Buja M, et al: Sickle cell trait and fatal rhabdomyolysis in football training: a case study. Med Sci Sports Exerc 2010; 42(1): 3-7.
42. Gardner JW, Kark JA: Fatal rhabdomyolysis presenting as mild heat illness in military training. Mil Med 1994; 159(2): 160-3.
43. Harrelson GL, Fincher AL, Robinson JB: Acute exertional rhabdomyolysis and its relationship to sickle cell trait. J Athl Train 1995; 30(4): 309-12.
44. Koppes GM, Daly JJ, Coltman CA Jr, Butkus DE: Exertion-induced rhabdomyolysis with acute renal failure and disseminated intravascular coagulation in sickle cell trait. Am J Med 1977; 63(2): 313-7.
45. Makaryus JN, Catanzaro JN, Katona KC: Exertional rhabdomyolysis and renal failure in patients with sickle cell trait: is it time to change our approach? Hematology 2007; 12(4): 349-52.
46. Patel DR, Gyamfi R, Torres A: Exertional rhabdomyolysis and acute kidney injury. Phys Sportsmed 2009; 37(1): 71-9.
47. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y: Complications associated with sickle cell trait: a brief narrative review. Am J Med 2009; 122(6): 507-12.
48. Wirthwein DP, Spotswood SD, Barnard JJ, Prahlow JA: Death due to microvascular occlusion in sickle-cell trait following physical exertion. J Forensic Sci 2001; 46(2): 399-401.
49. Eichner ER: Overcaffeination: low potassium and other perils. Curr Sports Med Rep 2011; 10(3): 122-3.
50. Salinger L, Daniels B, Ssangalli B, Bayer M: Recreational use of a bodybuilding supplement resulting in severe cardiotoxicity. Clin Toxicol (Phila) 2011; 49: 573-4.
51. The Expert Advisory Committee on Drugs: Assessment of 1,3 dimethylamylamine (DMAA). New Zealand Ministry of Health, 2009. Available at www.ndp.govt.nz/moh.nsf/Files/ndp./advice-to-eacddmaa-aug-2009.pdf; accessed April 20, 2012.
52. New pill ingredient worries ministry. TVNZ. October 4, 2008. Available at http://tvnz.co.nz/content/2174371/425826.xhtml; accessed February 4, 2012.
53. DMAA latest party pill substance to get ban. 3 News. March 8, 2012. Available at http://www.3news.co.nz/DMAA-latest-party-pillsubstance-to-get-ban/tabid/423/articleID/245691/Default.aspx; accessed March 28, 2012.
54. Hussien H, Khadem S, Charron M, et al: Classification of 1,3-Dimethylamylamine (DMAA). Health Canada; 2011:6. Available at http://www.scribd.com/doc/82744576/DMAA-Health-Canada-2011; accessed April 20, 2012.
55. Starling S: CRN UK on DMAA: "The law is clear. DMAA is illegal in the EU and should be stripped from shelves". NutraIngredients. com. January 9, 2012.
56. McCarthy CG, Farney TM, Canale RE Alleman RJ Jr, Bloomer RJ: A fnished dietary supplement stimulates lipolysis and metabolic rate in young men and women. Nutr Metab Insights 2012; 5: 23-31.
57. McCarthy CG, Canale RE, Alleman RJ Jr, Reed JP, Bloomer RJ: Biochemical and anthropometric effects of a weight loss dietary supplement in healthy men and women. Nutr Metab Insights 2012; 5: 13-22.
58. Farney TM, McCarthy CG, Canale RE, Alleman RJ Jr, Bloomer RJ: Hemodynamic and hematologic profile of healthy adults ingesting dietary supplements containing 1,3-dimethylamylamine and caffeine. Nutr Metab Insights 2012; 5: 1-12.
59. Bloomer RJ, McCarthy CG, Farney TM, Harvey IC: Effect of caffeine and 1,3-dimethylamylamine on exercise performance and blood markers of lipolysis and oxidative stress in trained men and women. J Caffeine Res 2011; 1(3): 169-77.
60. Bloomer RJ, Harvey IC, Farney TM, Bell ZW, Canale RE: Effects of 1,3-dimethylamylamine and caffeine alone or in combination on heart rate and blood pressure in healthy men and women. Phys Sportsmed 2011; 39(3): 111-20.
61. Bloomer RJ, Schilling BK, Whitehead PN, Farney TM: Safety profile of a dietary supplement containing 1,3 dimethylamylamine: a 10 week intervention study. Nutr Metab Insights 2012 (in press).
62. Rados C: Ephedra ban: no shortage of reasons. FDA Consum 2004; 38(2): 6-7.